|
Mar 28
|
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
|
|
Mar 28
|
Akebia Receives FDA Approval of Vafseo® (vadadustat) Tablets for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis
|
|
Mar 26
|
Akebia Awaits FDA Word On Second Crack At Vadadustat
|
|
Mar 17
|
Akebia Therapeutics, Inc. (NASDAQ:AKBA) Released Earnings Last Week And Analysts Lifted Their Price Target To US$4.33
|
|
Mar 16
|
Akebia Therapeutics Full Year 2023 Earnings: EPS Beats Expectations
|
|
Mar 14
|
Akebia Therapeutics Inc (AKBA) Reports Steady Revenue and a Profitable Quarter
|
|
Mar 14
|
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q4
|
|
Mar 14
|
Akebia Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
|
|
Mar 11
|
Akebia Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results
|
|
Jan 9
|
Akebia Therapeutics Announces Appointment of Nicholas Grund as Chief Commercial Officer
|
|
Dec 20
|
Akebia Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|
|
Dec 10
|
Akebia Therapeutics (NASDAQ:AKBA) shareholders have earned a 265% return over the last year
|
|
Dec 1
|
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Dec 1
|
Top Penny Stocks for Q4 2023
|
|
Nov 9
|
Q3 2023 Akebia Therapeutics Inc Earnings Call
|
|
Nov 8
|
Akebia Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights
|
|
Nov 2
|
Akebia Therapeutics Announces Favorable Payment Term Modification of Loan Agreement with Pharmakon Advisors
|
|
Oct 18
|
Akebia Therapeutics Announces Five Poster Presentations at ASN Kidney Week 2023
|
|
Aug 10
|
Akebia Therapeutics Provides Update on Form 10-Q Filing
|
|
Apr 25
|
Akebia Receives European Commission Approval for Vafseo™ (vadadustat) for the Treatment of Symptomatic Anaemia Associated with Chronic Kidney Disease in Adults on Chronic Maintenance Dialysis
|